Long-Term Outcome in Congenital Undescended Testis After Surgical Treatment by Orchidopexy
Launched by MEDICAL CENTER ALKMAAR · Nov 14, 2005
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • The orchidopexy has taken place in the Medical Center Alkmaar between 1986-2004
- • The indication concerned a congenital undescended testis
- • It concerns a first orchidopexy to the concerning testis
- Exclusion Criteria:
- • Orchidopexy has taken place on an other reason than congenital undescended testis (for example: torsio testis)
- • It concerns re-orchidopexy
About Medical Center Alkmaar
Medical Center Alkmaar is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence, the center employs a multidisciplinary approach, leveraging a team of experienced researchers and clinicians to conduct high-quality trials across various therapeutic areas. By fostering collaboration and utilizing state-of-the-art facilities, Medical Center Alkmaar aims to contribute significantly to the development of new treatments and therapies, ensuring that patients have access to cutting-edge medical care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alkmaar, Noord Holland, Netherlands
Patients applied
Trial Officials
W.W. M. Hack, MD, PhD
Study Director
Department of Pediatrics, Medical Centre Alkmar
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials